webinar
Oct. 27-28, 2025, Boston, MA, USA - Booth 114.
Read More

Disitamab vedotin

  CAS No.: 2136633-23-1   Cat No.: BADC-01604 4.5  

Disitamab vedotin is an antibody-drug conjugate consisting of the novel humanized anti-HER2 antibody (hertuzumab) conjugated to monomethyl auristatin E (MMAE) via a cleavable linker. Disitamab vedotin has been used in the research of HER2‑positive metastatic breast cancer therapy.

Disitamab vedotin

Structure of 2136633-23-1

Quality
Assurance

Worldwide
Delivery

24/7 Customer
Support
Category
Antibody-Drug Conjugates (ADCs)

* For research and manufacturing use only. We do not sell to patients.

Size Price Stock Quantity
-- $-- In stock

Looking for different specifications? Click to request a custom quote!

Capabilities & Facilities

Popular Publications Citing BOC Sciences Products
Synonyms
RC48
Appearance
Solid

Disitamab vedotin, a promising agent in cancer therapy, stands out for its mechanism of action and specificity. This medication is an antibody-drug conjugate (ADC), blending the benefits of targeted therapy with the potency of cytotoxic agents. Disitamab vedotin targets HER2 (human epidermal growth factor receptor 2), a protein overexpressed in various cancers such as breast, gastric, and bladder cancer. By specifically binding to HER2-expressing cells, this drug ensures that the cytotoxic agent is delivered directly to the tumor site, minimizing damage to healthy tissues and thereby improving patient tolerability and outcomes.

The core technology behind Disitamab vedotin is the conjugation of a monoclonal antibody with a cytotoxic molecule, linked by a stable connection. The antibody component selectively binds to the HER2 receptor on the cancer cell surface, while the attached cytotoxic agent, vedotin, is a potent microtubule inhibitor. Upon binding, the complex is internalized by the cancer cell, where the cytotoxic agent is released, leading to cell death through disruption of the microtubule network essential for cell division. This specificity not only enhances efficacy but also reduces systemic exposure to the cytotoxic agents compared to traditional chemotherapy.

One of the key applications of Disitamab vedotin in drug discovery lies in its ability to address unmet medical needs in oncology, particularly for those patients who exhibit resistance to existing HER2-targeted therapies. Its innovative design offers an alternative for cancers that have become refractory to trastuzumab and other similar drugs. Moreover, the development of such ADCs expands the potential of personalized medicine, as treatment can be tailored based on the expression levels of HER2 in tumors, thus maximizing therapeutic outcomes while minimizing adverse effects.

The success of Disitamab vedotin also underscores the importance of ADCs in the broader landscape of drug development. It demonstrates a strategic shift towards bioconjugation techniques that merge biological targeting with chemical cytotoxicity. This paradigm is not only applicable to HER2-driven malignancies but can also be adapted to other oncogenes involved in different cancer types. The method serves as a modular framework that can incorporate different antibodies and cytotoxic agents, potentially revolutionizing the way we approach the treatment of various cancers.

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Related Products

Contact our experts today for pricing and comprehensive details on our ADC offerings.

You May Also Be Interested In

From cytotoxin synthesis to linker design, discover our specialized services that complement your ADC projects.

ADC Manufacturing Services ADC cGMP Manufacturing ADC Fill/Finish ADC Purification ADC Formulation Development Antibody–Drug Conjugate Solutions ADC Early Discovery ADC Process Development ADC Preclinical Studies

Unlock Deeper ADC Insights

Learn more about payload design, linker strategies, and integrated CDMO support through our curated ADC content.

Current Technical Development Trends in Antibody-Drug Conjugate (ADC) Drugs The Development History of ADC Drugs What are Antibody Drug Conjugates? New FDA-Approved ADC: Disitamab Vedotin for Bladder Cancer New ADC Drug for Lymphoma: Loncastuximab Tesirine Overview of Antibody-Drug Conjugate (ADC) Production Technologies ADC Drugs: Unlocking New Frontiers in Tumor Treatment How to Design A Good ADC Drug? Tivdak: FDA's First Approved Tissue Factor-Targeted Antibody-Drug Conjugate How Endocytosis Influences the Receptor Targeting Mechanism of ADC Drugs?

Explore More ADC Products

Find exactly what your project needs from our expanded range of ADCs, offering flexible options to fit your timelines and goals.

ADC Cytotoxin

Powerful Targeted Cancer Solutions

ADC  Cytotoxin with Linker

Enhanced Stability And Efficacy

ADC Linker

Precise Conjugation For Success

Antibody-Drug  Conjugates (ADCs)

Maximized Therapeutic Performance

Auristatins

Next-Level Tubulin Inhibition

Calicheamicins

High-Impact DNA Targeting

Camptothecins

Advanced Topoisomerase Inhibition

Daunorubicins / Doxorubicins

Trusted Anthracycline Payloads

Duocarmycins

Potent DNA Alkylation Agents

Maytansinoids

Superior Microtubule Disruption

Pyrrolobenzodiazepines

Ultra-Potent DNA Crosslinkers

Traditional Cytotoxic Agents

Proven Chemotherapy Solutions

Cleavable Linker

Precise Intracellular Drug Release

Non-Cleavable Linker

Exceptional Long-Term Stability

Historical Records: N-succinimidyl-5-(2-pyridyldithio)valerate | SPDP-C6-Gly-Leu-NHS ester | Tusamitamab ravtansine | Val-Cit-PAB-MMAF | SPDPH | Sirtratumab vedotin | Patritumab deruxtecan | Fmoc-D-Val-Cit-PAB | N-succinimidyl 4-(5-nitro-pyridin-2-yldithio)-pentanoate | Cantuzumab mertansine | Disitamab vedotin
Send Inquiry
Verification code
Inquiry Basket